What is Calquence
AcalabrutinibThe Generic name of this drug
Treatment SummaryAcalabrutinib is a medication used to treat certain types of blood cancers, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and Mantle Cell Lymphoma. It is a second-generation Bruton Tyrosine Kinase (BTK) inhibitor that was designed to be more potent and selective than other BTK inhibitors and hopefully cause fewer side effects. The FDA approved acalabrutinib in October 2017 and gave it Priority Review, Breakthrough Therapy, and Orphan Drug designations. Acalabrutinib is being studied in over 35 clinical trials in 40 countries
Calquenceis the brand name
Calquence Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Calquence
Acalabrutinib
2017
2
Approved as Treatment by the FDA
Acalabrutinib, otherwise called Calquence, is approved by the FDA for 4 uses like Mantle Cell Lymphoma and ≥ 1 prior therapy for Mantle cell lymphoma .Mantle Cell Lymphoma
≥ 1 prior therapy for Mantle cell lymphoma
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Effectiveness
How Calquence Affects PatientsAcalabrutinib is a medication that blocks the growth, movement, and sticking of B cells. It needs to be taken twice a day and can cause atrial fibrillation, other forms of cancer, low levels of blood cells, bleeding, and infection.
How Calquence works in the bodyMantle Cell Lymphoma (MCL) is an aggressive type of cancer that affects the lymphocytes, or white blood cells, in the body. It is difficult to treat and often leads to relapse. Acalabrutinib is a drug designed to fight MCL by targeting a molecule called Bruton Tyrosine Kinase (BTK). This molecule helps lymphocytes grow and multiply, so by blocking it, acalabrutinib can stop the cancerous cells from spreading. Acalabrutinib is more powerful and selective than other drugs used to treat MCL, and it has fewer
When to interrupt dosage
The recommended measure of Calquence is contingent upon the diagnosed state, for instance Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma. The dosage likewise changes in accordance to the administration technique (e.g. Oral or Capsule) stated in the table hereunder.Condition
Dosage
Administration
Mantle Cell Lymphoma
100.0 mg,
Oral, Capsule, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Tablet, film coated - Oral, Tablet, film coated, Capsule - Oral,
Chronic Lymphocytic Leukemia
100.0 mg,
Oral, Capsule, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Tablet, film coated - Oral, Tablet, film coated, Capsule - Oral,
Small Lymphocytic Lymphoma
100.0 mg,
Oral, Capsule, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Tablet, film coated - Oral, Tablet, film coated, Capsule - Oral,
≥ 1 prior therapy for Mantle cell lymphoma
100.0 mg,
Oral, Capsule, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Tablet, film coated - Oral, Tablet, film coated, Capsule - Oral,
Warnings
There are 20 known major drug interactions with Calquence.Common Calquence Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Acalabrutinib.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Acalabrutinib.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Acalabrutinib.
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Acalabrutinib.
Axitinib
Major
The metabolism of Axitinib can be decreased when combined with Acalabrutinib.
Calquence Toxicity & Overdose RiskThere is currently limited information available on the toxicity of acalabrutinib.
Calquence Novel Uses: Which Conditions Have a Clinical Trial Featuring Calquence?
338 active trials are being conducted to investigate the potential of Calquence in alleviating Mantle Cell Lymphoma, ≥ 1 prior therapy for Mantle cell lymphoma and Small Lymphocytic Lymphoma.Condition
Clinical Trials
Trial Phases
Chronic Lymphocytic Leukemia
169 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1
Mantle Cell Lymphoma
100 Actively Recruiting
Phase 2, Phase 3, Phase 1, Early Phase 1, Not Applicable
≥ 1 prior therapy for Mantle cell lymphoma
0 Actively Recruiting
Small Lymphocytic Lymphoma
79 Actively Recruiting
Phase 2, Not Applicable, Phase 3, Phase 1
Calquence Reviews: What are patients saying about Calquence?
5Patient Review
5/30/2022 The treatment has been very effective for me so far, though I have experienced some of the listed side effects. Headaches, nausea, and muscle cramps are all things I've dealt with since starting the medication. However, compared to cancer, these are relatively minor issues that I'm more than happy to deal with.
5Patient Review
5/5/2020 So far, this therapy is working well for me. I'm using it after imbruvica failed due to Afib. There are no real side effects except for a few headaches. White blood cells are normal. You do have to take it twice a day, which can be difficult to remember; thankfully, I use a pill box.
Patient Q&A Section about calquence
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What is Calquence used for?
"CALQUENCE is a drug used to treat cancer in adults. It is prescribed for those who have received previous treatment for their cancer, or for those with chronic lymphocytic leukemia or small lymphocytic lymphoma."
Answered by AI
What kind of drug is Calquence?
"Acalabrutinib is a medication used to treat certain types of cancer, such as [mantle cell lymphoma](https://www.withpower.com/clinical-trials/mantle-cell-lymphoma), small lymphocytic lymphoma (SLL), and chronic lymphocytic leukemia (CLL). Acalabrutinib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors."
Answered by AI
Is Calquence considered chemotherapy?
"CALQUENCE can be used as a targeted alternative to traditional chemotherapy for patients with CLL/SLL who have already received another treatment. CALQUENCE is a kinase inhibitor that affects the growth of CLL/SLL cancer cells."
Answered by AI
How effective is Calquence?
"In the final analysis of ASCEND, an estimated 82% of patients with relapsed or refractory CLL treated with Calquence remained alive and free from disease progression at 18 months compared with only 48% of patients on rituximab combined with idelalisib or bendamustine."
Answered by AI